Founder Reflections on 2023

As I reflect on this past year, 2023 finally brought us some wins in reproductive health. And I personally had the opportunity to contribute to landmark steps forward. ⭐️ The FDA made long awaited changes to the mifepristone REMS program to allow pharmacies to dispense the essential medication. I was part of the research team…

Read More

Pharmacists Can Now Dispense Mifepristone Under Updated REMS Program

What Does the January 2023 Update Mean for Mifepristone Dispensing? Mifepristone is a medication that is used to end an early pregnancy. It has been available in the United States since 2000 and is widely used as a safe and effective option for ending a pregnancy during the first 10 weeks. As of January 2023,…

Read More

Upcoming Changes to the Mifepristone REMS Program: Implications for Pharmacy Practice

Pharmacists in the community setting may soon have the opportunity to ease access to medication abortion in the United States. In the coming months, mifepristone (Mifeprex) is anticipated to have an updated Risk Evaluation and Mitigation Strategy (REMS) Program that allows dispensing through local brick-and-mortar and mail-order pharmacies. This change will integrate pharmacists into abortion…

Read More

Reproductive Health During COVID: Eliminating FDA’s Burdensome Barriers to Mifepristone

What is Mifepristone?  Mifepristone is the primary component in the FDA-approved regimen taken to terminate pregnancies through 10 weeks gestation and is seen as an alternative to a surgical procedure.1 Many patients view this as less invasive, allowing for more privacy and control over a personal situation. The standard oral regimen includes mifepristone 200mg followed…

Read More